BD Q1 revenue $5.25B beats; closes Waters deal; affirms FY26 guidance

BECTON DICKINSON & CO

2026-Q1 EPS reported $1.34 vs consensus $2.80 ▼ miss (-52.2%)

Revenue $5.252B (+1.6% reported, +0.4% FX neutral); GAAP EPS $1.34, adjusted EPS $2.91.
BD to close combination of Biosciences & Diagnostic Solutions business with Waters Corporation on Feb 9, 2026.
Affirms FY26 revenue growth guidance; provides New BD adjusted diluted EPS guidance.
Announced $110M investment for Neopak syringe production in Nebraska; FDA clearance for EnCor EnCompass biopsy system.
Adjusted diluted EPS $2.91, down 15.2% YoY on reported basis but beat expectations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.